For: | Kostapanos MS, Elisaf MS. JUPITER and satellites: Clinical implications of the JUPITER study and its secondary analyses. World J Cardiol 2011; 3(7): 207-214 [PMID: 21860701 DOI: 10.4330/wjc.v3.i7.207] |
---|---|
URL: | https://www.wjgnet.com/1949-8462/full/v3/i7/207.htm |
Number | Citing Articles |
1 |
Michael S. Kostapanos, Christos V. Rizos, Moses S. Elisaf. Benefit–Risk Assessment of Rosuvastatin in the Treatment of Atherosclerosis and Related Diseases. Drug Safety 2014; 37(7): 481 doi: 10.1007/s40264-014-0169-4
|
2 |
Michael S. Kostapanos, Paul J. Cacciottolo, Annette Hubsch, Holly Pavey, James Hurlock, Kaisa Maki-Petaja, Ian B. Wilkinson, Joseph Cheriyan. Investigating the lowest threshold of vascular benefits from LDL cholesterol lowering with a PCSK9 mAb inhibitor (alirocumab) in healthy volunteers – a mechanistic physiological study (INTENSITY-LOW): protocol and study rationale. Journal of Drug Assessment 2019; 8(1): 167 doi: 10.1080/21556660.2019.1677673
|
3 |
Xin Su, Dao-quan Peng. New insights into ANGPLT3 in controlling lipoprotein metabolism and risk of cardiovascular diseases. Lipids in Health and Disease 2018; 17(1) doi: 10.1186/s12944-018-0659-y
|
4 |
Russell H. Samson, Deepak G. Nair. Influence and Critique of the JUPITER Trial (Statins v No Statins for Primary Prevention of Cardiovascular Events in Patients with Normal Lipids and Elevated C-Reactive Protein). Seminars in Vascular Surgery 2011; 24(3): 172 doi: 10.1053/j.semvascsurg.2011.10.005
|
5 |
László Szapáry, Gergely Fehér. Effectiveness of generic rosuvastatin in patients with ischaemic cerebrovascular disease. Orvosi Hetilap 2012; 153(22): 857 doi: 10.1556/OH.2012.29390
|
6 |
Michael S. Kostapanos, Moses S. Elisaf, Dimitri P. Mikhailidis. Targeting cardiovascular risk: the impact of age, gender and compliance to treatment. Current Medical Research and Opinion 2012; 28(9): 1415 doi: 10.1185/03007995.2012.715518
|
7 |
Vanessa Leite Andrade, Izabella Batistelli do Valle, Valeria Cristina Sandrim. Simvastatin therapy decreases MMP‐9 levels in obese women. The Journal of Clinical Pharmacology 2013; 53(10): 1072 doi: 10.1002/jcph.146
|
8 |
Amir Avan, Seyedeh Belin Tavakoly Sany, Majid Ghayour‐Mobarhan, Hamid Reza Rahimi, Mohammad Tajfard, Gordon Ferns. Serum C‐reactive protein in the prediction of cardiovascular diseases: Overview of the latest clinical studies and public health practice. Journal of Cellular Physiology 2018; 233(11): 8508 doi: 10.1002/jcp.26791
|
9 |
Tomáš Šálek, Alena Adamíková, Petr Ponížil. The fat mass, estimated glomerular filtration rate, and chronic inflammation in type 2 diabetic patients. Journal of Clinical Laboratory Analysis 2020; 34(6) doi: 10.1002/jcla.23229
|